Beam Therapeutics Inc. (BEAM) News
Filter BEAM News Items
BEAM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BEAM News Highlights
- BEAM's 30 day story count now stands at 6.
- Over the past 19 days, the trend for BEAM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about BEAM are DEC, BASE and COMP.
Latest BEAM News From Around the Web
Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
2 Cathie Wood Stocks That Could Soar in 2024, According to Wall StreetWall Street is uber-bullish on these two Ark Invest holdings. |
11 Most Promising Biotech Stocks to Buy According to AnalystsIn this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Buy According to Analysts. The biotech industry is making a resurgence […] |
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeuticsbluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog. |
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of DirectorsCAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors. “Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry’s premier autologous cell therapy comp |
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to TradeThe mean of analysts' price targets for Beam Therapeutics Inc. (BEAM) points to an 81.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Beam Therapeutics Inc's Chief Legal Officer Christine Bellon Sells 10,000 SharesBeam Therapeutics Inc (NASDAQ:BEAM), a biotechnology company specializing in the development of precision genetic medicines through base editing, has recently seen a significant insider sell by its Chief Legal Officer, Christine Bellon. |
14 Best Short-Term Stocks to Invest InIn this article, we will take a look at 14 best short-term stocks to invest in. To skip our analysis of the recent market activity, you can go directly to see the 5 Best Short-Term Stocks to Invest In. Momentum investing is a key strategy used for short term investments, typically grouped in with other […] |
The 3 Best Gene Editing Stocks on the Frontier of MedicineSome of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December. |
Is Beam Therapeutics Stock a Buy Now?When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity compared to a few of its competitors, few would claim that its technology platform is unimpressive. Like most biotech stocks that haven't yet commercialized any medicines, Beam is living on borrowed time. |